How often does tigecycline cause abnormal liver blood tests?
In the provided information, there is no specific incidence rate for liver-test abnormalities with tigecycline (for example, the percentage of patients who develop elevated ALT/AST or bilirubin).
Which liver tests are typically affected with tigecycline?
The available information here does not list which liver parameters (ALT, AST, alkaline phosphatase, or bilirubin) were reported, or how often each one was abnormal.
Is the rate different by population or regimen (e.g., ICU vs. trials, dose, duration)?
No details are provided that would let me compare incidence across subgroups (such as ICU vs. non-ICU) or by dose/duration.
What to check for in labeling or trial reports
To get the incidence, you’d typically look for sections in the tigecycline prescribing information or clinical trial safety tables reporting:
- treatment-emergent ALT/AST elevations (often graded by multiples of the upper limit of normal, ULN)
- bilirubin elevations
- cases that led to dose interruption, discontinuation, or signs of hepatic injury
If you share a label excerpt, I can compute the incidence
If you paste the relevant safety-table rows (or the tigecycline label text/table you’re using), I can translate it into an incidence statement (e.g., “X% had ALT >3× ULN”) and distinguish liver enzymes vs bilirubin.
Sources
No sources were provided in the prompt, and no incidence data for tigecycline liver-test abnormalities were included here.